A chimeric antigen receptor (CAR)-T cell therapy is a type of treatment in which a patient's T cells, lymphocytes of a type produced or processed by the thymus gland and actively participating in the immune response, are modified to attack cancer cells.

Increasing prevalence of cancer is expected to boost growth of the global CAR-T cell therapy market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018. Moreover, increasing preference for genetically engineered treatment approaches for the effective treatment of various types of cancers is also expected to aid in growth of the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/102

Increasing investments related to CAR-T cell therapy are expected to fuel growth of the global CAR-T cell therapy market over the forecast period. For instance, in 2016, Novartis International AG invested around US$ 9 billion in R&D in CAR-T cell therapy. Other companies that are actively involved in R&D in CAR-T cell therapy for diffuse large B-cell lymphoma and relapsed/refractory acute lymphoblastic leukemia include Juno Therapeutics and Kite Pharma Inc.

Among regions, North America is expected to hold dominant position in the global CAR-T cell therapy market over the forecast period. This is owing to increasing prevalence of cancer in the region. For instance, according to Fight Colorectal Cancer Organization, there will be an estimated 140,250 new cases of colorectal cancer in 2019 in the U.S.

Europe is expected to follow North America in terms of market share. However, conducting country-specific clinical trials across the region is expected to be a major challenge for growth of the market.

Among the types of therapy, the CD 19-based therapy segment is expected to hold dominant position in the global CAR-T cell therapy market over the forecast period. This is owing to increasing R&D related to CD 19 for the treatment of leukemia. Other antigens such as CD 20 and CD 22 are also expected to witness significant growth.

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in February 2020, Precision BioSciences announced its plan to initiate a clinical trial for its new CAR T-cell therapy candidate, PBCAR269A, for the treatment of relapsed or refractory multiple myeloma. The Phase 1/2a trial (NCT04171843) is expected to begin enrolling eligible adults in March at multiple U.S. sites.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/car-t-cell-therapy-market-102

Moreover, in March 2020, Tessa Therapeutics received the U.S. Food and Drug Administration (FDA)’s Regenerative Medicine Advanced Therapy designation to its investigational CD30-targeted CAR T-cell therapy for the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

Key Takeaways

• Increasing prevalence of cancer to augment growth of the global CAR-T cell therapy market over the forecast period
• North America is expected to account for 58.3% of overall industry share in 2018
• CD 19 segment is expected to touch a billion dollar mark by 2023
• Major players operating in the global CAR-T cell therapy market include, Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/102

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737